Trial Summary
What is the purpose of this trial?As the treatments for liver disease and the availability of liver transplantation have progressed, the number of patients with end stage liver disease continues to increase. This has increased the need to risk-stratify patients with cirrhosis to better direct their treatments and provide an accurate prognosis for their outcomes. The traditional assessment of the liver patient has been limited to imaging, static measures of "liver function tests" and liver biopsy. This protocol is designed to increase the spectrum of tests in the evaluation of the patient with end stage liver disease.
Eligibility Criteria
This trial is for adults aged 18 to 80 with end-stage liver disease, living liver donors, or those with congenital heart disease. Participants must be able to give written consent and follow study rules. Only patients with severe fibrosis as shown by specific tests or clinical evidence can join.Inclusion Criteria
I am between 18 and 80 years old.
I have end-stage liver disease, am a living liver donor, or have congenital heart disease.
My liver disease is in an advanced stage, indicated by severe scarring.
Treatment Details
The trial is testing new quantitative liver function tests using cholates. These tests aim to better evaluate the condition of patients with advanced liver disease and could help in managing their treatment and predicting outcomes more accurately.
1Treatment groups
Experimental Treatment
Group I: Cholates CompoundExperimental Treatment1 Intervention
Find a clinic near you
Research locations nearbySelect from list below to view details:
Baylor University Medical CenterDallas, TX
Loading ...
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor